Shilpa Medicare Ltd vs Windlas Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Shilpa Medicare Ltd is ₹ 546.2 as of 12 Jun 15:30 . The P/E Ratio of Shilpa Medicare Ltd changed from 18.4 on March 2021 to 82.8 on March 2025 . This represents a CAGR of 35.10% over 5 yearsThe P/E Ratio of Windlas Biotech Ltd changed from 12 on March 2022 to 35.8 on March 2025 . This represents a CAGR of 31.42% over 4 years The Market Cap of Shilpa Medicare Ltd changed from ₹ 2721 crore on March 2021 to ₹ 6483 crore on March 2025 . This represents a CAGR of 18.96% over 5 yearsThe Market Cap of Windlas Biotech Ltd changed from ₹ 457.9 crore on March 2022 to ₹ 2176 crore on March 2025 . This represents a CAGR of 47.65% over 4 years The revenue of Shilpa Medicare Ltd for the Mar '26 is ₹ 482 crore as compare to the Dec '25 revenue of ₹ 410.54 crore. This represent the growth of 17.41% The revenue of Windlas Biotech Ltd for the Mar '26 is ₹ 242.85 crore as compare to the Dec '25 revenue of ₹ 237.67 crore. This represent the growth of 2.18% The ebitda of Shilpa Medicare Ltd for the Mar '26 is ₹ 164.72 crore as compare to the Dec '25 ebitda of ₹ 101.89 crore. This represent the growth of 61.66% The ebitda of Windlas Biotech Ltd for the Mar '26 is ₹ 29.64 crore as compare to the Dec '25 ebitda of ₹ 28.95 crore. This represent the growth of 2.38% The net profit of Shilpa Medicare Ltd changed from ₹ 14.06 crore to ₹ 107.79 crore over 8 quarters. This represents a CAGR of 176.88% The net profit of Windlas Biotech Ltd changed from ₹ 13.48 crore to ₹ 15.99 crore over 8 quarters. This represents a CAGR of 8.91% The Dividend Payout of Shilpa Medicare Ltd changed from 4.86 % on March 2021 to 14.01 % on March 2025 . This represents a CAGR of 23.58% over 5 yearsThe Dividend Payout of Windlas Biotech Ltd changed from 19.79 % on March 2022 to 20.04 % on March 2025 . This represents a CAGR of 0.31% over 4 years .

About Shilpa Medicare Ltd

Shilpa Medicare Limited, formerly known as Shilpa Antibiotics Private Limited was incorporated as a Private Company on November 20, 1987.
The Company changed the status to Public and the name of the Company changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service.
The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology.
It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets.

About Windlas Biotech Ltd

Windlas Biotech Limited, formerly known as Windlas Biotech Private Limited was incorporated in 2001.
The Company got converted from a Private Limited to a Public Limited Company and the name of the Company was changed to Windlas Biotech Limited'.
A fresh Certificate of Incorporation dated April 15, 2021, granted by the Registrar of Companies, Uttarakhand at Dehradun. The Company is engaged in manufacturing and trading of pharmaceutical products.
Their manufacturing plants are located at Dehradun in Uttarakhand.
It has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products; domestic trade generics and over-the-counter (OTC) brands; and exports. The Company commenced operations at Dehradun Plant -IV in 2010.

FAQs for the comparison of Shilpa Medicare Ltd and Windlas Biotech Ltd

Which company has a larger market capitalization, Shilpa Medicare Ltd or Windlas Biotech Ltd?

Market cap of Shilpa Medicare Ltd is 10,682 Cr while Market cap of Windlas Biotech Ltd is 1,694 Cr

What are the key factors driving the stock performance of Shilpa Medicare Ltd and Windlas Biotech Ltd?

The stock performance of Shilpa Medicare Ltd and Windlas Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Shilpa Medicare Ltd and Windlas Biotech Ltd?

As of June 14, 2026, the Shilpa Medicare Ltd stock price is INR ₹546.2. On the other hand, Windlas Biotech Ltd stock price is INR ₹821.1.

How do dividend payouts of Shilpa Medicare Ltd and Windlas Biotech Ltd compare?

To compare the dividend payouts of Shilpa Medicare Ltd and Windlas Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.